Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of the Safety and Efficacy of Third-generation Oncolytic TS-2021 in the Treatment of Recurrent Malignant Gliomas

NCT06585527 is registered in ClinicalTrials.gov with Beijing Neurosurgical Institute as lead sponsor.

NCT NCT06585527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06585527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of the Safety and Efficacy of Third-generation Oncolytic TS-2021 in the Treatment of Recurrent Malignant Gliomas
Lead sponsor
Beijing Neurosurgical Institute
Phase
Phase 1
Overall status
Unknown status
Start date
August 29, 2024
Completion date
January 1, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, glioma, malignant